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Abstract 
 
Recent studies from Finland reported that maternal pelvic size predicted daughters’ breast 
and ovarian cancer, possibly because maternal pelvic size is a marker for in utero 
hormone exposure.  We sought to replicate this association in 3845 women born 1915-
1929 in Uppsala, Sweden, and followed from 1960 to 2002.  Archived obstetric records 
provided the standard measures of maternal pelvic size (intercristal distance, interspinous 
distance, the intercristal-interspinous difference and the external conjugate distance).  The 
Swedish cancer registry ascertained cancer incidence, with 273 cohort members 
developing primary breast cancer and 52 developing primary ovarian cancer during the 
follow-up period.  There was no evidence (p>0.1) of an association between any measure 
of maternal pelvic size and incidence of either breast or ovarian cancer.  This was true 
both before and after adjustment for various characteristics of the women and their 
mothers, and in analyses stratified by age at diagnosis (under age 50 vs. age ≥50, as a 
proxy for pre- and post-menopausal ages).  There was also no evidence of an association 
in subgroup analyses restricted specifically to those groups in which the Finnish data 
found the greatest effect.  Our study is of comparable size to the Finnish studies and 
highly powered (>99%) to detect effects of the magnitude they reported.  Our non-
replication therefore casts doubt on the link between maternal pelvic size and risk of 
breast and ovarian cancer in the offspring. 
 
Key Words: pelvic size, breast cancer, ovarian cancer, intergenerational, developmental 
origins of health and disease 
 
 
Introduction 
 
Barker et al. recently reported that maternal pelvic size predicted breast and ovarian 
cancer in 4102 Finnish women born between 1934-1944 and followed from 1971-2003 
(1, 2).  They investigated four standard measures of maternal pelvic size: intercristal 
distance (the maximal distance between the iliac crests); interspinous distance (distance 
between the anterior-superior iliac spines); the difference between the intercristal and 
interspinous distances; and external conjugate distance (distance from front of the pubic 
bone to the fifth lumbar vertebrae).  206 of their cohort members developed primary 
breast cancer, with higher incidence among women whose mother had a larger intercristal 
distance and a larger interspinous-intercristal difference.  39 developed primary ovarian 
cancer, with higher incidence among women whose mother had a larger interspinous 
distance.  Barker et al. hypothesise that pelvic size is a marker for mother’s hormone 
profile, and that this in utero exposure increases the daughter’s risk.   
 
Maternal pelvic size and breast/ovarian cancer 3 
Methods 
 
Sample 
 
The Uppsala Birth Cohort Multigenerational Study (UBCoS Multigen) has been 
described previously (3-5).  Briefly, the cohort comprises all live births between 1915-
1929 in the Uppsala Academic Hospital, Sweden.  Archived obstetric records provided 
information about cohort members and their mothers at birth, and record linkage 
provided data from routine registers up to 2002.  This included the Swedish cancer 
registry, established 1 January 1960.  
 
Of the 6781 females live births, 751 died before 1960, 63 emigrated before 1960, and 202 
were never traced.  3845/5765 (66.7%) of the remainder had maternal pelvis 
measurements, and these are the starting population for our analyses.  Pelvis 
measurements were more complete after 1924 (31.7-50.1% with data pre-1924 vs. 
≥93.4% after) and for primiparous women (72.1% with data vs. 63.2% for multiparous).  
There was no evidence (p>0.05) that missing pelvis measurements predicted breast or 
ovarian cancer in daughters. 
 
Statistical methods 
 
We fitted Cox proportional hazards models, running separate models for breast and 
ovarian cancer.  Follow-up started on 1 January 1960 and continued until the date of 
death, emigration, diagnosis with any primary cancer or until 31 December 2002.   The 
woman’s age defined the timescale.  To adjust for possible cohort or period effects, we 
divided birth year into three bands (1915-19, 1920-24, 1925-29) and included this as a 
categorical variable in all models.  We used the same cut-offs as Barker et al. for 
categorizing pelvic measurements and also present analyses using the continuous 
measurements. 
 
We then assessed the effect of adjusting for each potential confounder listed in Table 1 
individually, and of adjusting for all of them simultaneously.  We banded the continuous 
confounders into between five and eight categories of approximately equal size, and 
modeled these as categorical variables.   
 
Barker et al. report that the effect of intercristal distance on breast cancer was greatest in 
multiparous mothers and infants born at ≥40 weeks, and that the effect of interspinous 
distance on ovarian cancer was greatest in mothers who had menarche before age 14 and 
were under 160cm tall.  We conducted sensitivity analyses restricting our analyses to 
these subgroups, except for mother’s height which was not recorded for our cohort. To 
assess whether the effect of maternal pelvic size was modified by menopausal status, we 
also conducted separate analyses for ages <50 and ≥50 years, using these as proxies for 
pre-menopausal and post-menopausal ages. 
 
Results 
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The characteristics of the study population and their mothers are summarized in Table 1.  
Among our 3845 study members, 273 developed primary breast cancer and 52 developed 
primary ovarian cancer by 31 December 2002 (total person years at risk 142826.3). 
 
Table 1: Characteristics of study population and their mothers (N=3845) 
 Number 
with data 
Mean (SD) or 
proportion 
Range 
Pelvis measurements of mother    
   Intercristal distance (cm) 3845 28.3 (1.6) 20, 35 
   Interspinous distance (cm) 3845 25.3 (1.7) 17.5,  39 
   Intercristal minus interspinous distance (cm) 3845 2.9 (1.3) -10,  9 
   External conjugate (cm) 3332 20.1 (1.5) 10, 34 
    
Cancer incidence of daughter    
   Age at breast cancer diagnosis (years) 273 61.9 (11.1) 36.4, 85.4 
   Age at ovarian cancer diagnosis (years) 52 60.3 (12.0) 36.6, 86.3 
    
Potential confounders    
Mother’s characteristics    
   Mother’s age at menarche (years) 3811 14.7 (1.5) 11, 22 
   Mother’s age at child’s birth (years) 3845 28.1 (6.5) 15, 47 
   Mother’s parity at child’s birth 3845 2.6 (2.3) 1, 16 
Daughter’s characteristics at birth    
   Birthweight (g) 3822 3367.8 (521.5) 1180, 5350 
   Birth length (cm) 3838 50.2 (2.3) 38, 59 
   Head circumference (cm) 3744 34.3 (1.5) 23, 46 
   Gestational age (weeks) 3713 39.6 (2.1) 29, 47 
Daughter’s adult characteristics    
   Post-elementary education 3791 4.3% -- 
   Had at least one child 3845 83.6% -- 
   Number of children among those who had at 
least one child 3214 2.3 (1.3) 1, 13 
   Age at first birth among those who had at 
least one child (years) 3214 24.1 (4.6) 17, 41 
SD = standard deviation 
 
 
Table 2 presents the hazard ratios for breast and ovarian cancer for each of the pelvic 
measures.  In no case was there evidence of an association (p>0.1); this remained true 
when entering the pelvic measurements as categorical variables or with quadratic terms.   
There was likewise no evidence at the 5% level of an association after adjusting for any 
potential confounder listed in Table 1, after stratifying our analyses between women aged 
<50 and those aged ≥50 years, or after restricting our analyses to the subgroups in which 
Barker et al. report the greatest effect. 
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Table 2: Hazard ratios for breast and ovarian cancer by maternal pelvic measurements 
 Breast cancer   Ovarian cancer   
 Hazard ratio & 
95% CI 
No. 
cases 
(N=273) 
No. women 
(N=3845)† 
Hazard ratio & 
95% CI 
No. 
cases 
(N=52) 
No. 
women 
(N=3845) 
Intercristal  
distance (cm) 
      
   ≤28.0 1 145 2122 1 28 2122 
   28.5-30.0 1.18 (0.92 – 1.51) 111 1391 1.05 (0.59  –  1.89) 19 1391 
   ≥30.5 0.76 (0.46 – 1.26) 17 332 1.20 (0.46  –  3.11) 5 332 
  P-value for heterogeneity 0.16   0.93   
  Change per 1cm increase 1.00 (0.93 – 1.07) 273 3845 1.05 (0.89  –  1.24) 52 3845 
  P-value for linear trend 0.96   0.55   
 
Interspinous (cm) 
   
 
  
   ≤28.0 1 72 1037 1 10 1037 
   28.5-30.0 1.11 (0.83  –  1.48) 141 1933 1.69 (0.81  –  3.53) 28 1933 
   ≥30.5 1.03 (0.73  –  1.47) 60 875 1.92 (0.84  –  4.42) 14 875 
  P-value for heterogeneity 0.77   0.27   
  Change per 1cm increase 0.98 (0.92  –  1.05) 273 3845 1.11 (0.96  –  1.29) 52 3845 
  P-value for linear trend 0.60   0.17   
Intercristal minus 
interspinous (cm) 
   
 
  
   ≤2.0 1 84 1228 1 20 1228 
   2.5 1.21 (0.76  –  1.92) 23 268 0.99 (0.37  –  2.65) 5 268 
   3.0 0.87 (0.63  –  1.19) 74 122 0.66 (0.33  –  1.30) 15 122 
   ≥3.5 1.16 (0.85  –  1.58) 92 1129 0.54 (0.25  –  1.15) 12 1129 
  P-value for heterogeneity 0.25   0.35   
  Change per 1cm increase 1.03 (0.94  –  1.13) 273 3845 0.90 (0.74  –  1.09) 52 3845 
  P-value for linear trend 0.53   0.27   
External conjugate 
distance (cm) 
   
 
  
   ≤19.0 1 72 1000 1 14 1000 
   19.5-21.0 0.99 (0.74  –  1.32) 129 1831 0.81 (0.41  –  1.61) 20 1831 
   ≥21.5 1.08 (0.72  –  1.60) 38 501 0.92 (0.35  –  2.41) 6 501 
  P-value for heterogeneity 0.90   0.83   
  Change per 1cm increase 1.02 (0.94  –  1.11) 239 3332 0.98 (0.79  –  1.22) 40 3332 
  P-value for linear trend 0.64   0.88   
† 513 women had missing data on external conjugate distance, giving a total of 3332. 
All analyses adjust for birth year with age defining the timescale. 
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Discussion 
 
UBCoS Multigen provides a unique opportunity to test the hypotheses proposed by 
Barker et al. (1, 2). Unlike their findings from Finland, our Swedish cohort provided no 
evidence that maternal pelvic size predicts daughters’ breast or ovarian cancer.  This is 
despite a close similarity in our methods, and a close similarity between our study 
populations in terms of pelvic sizes and cancer incidence.  Our null findings were robust 
to adjustment for confounders and sensitivity analyses, including analyses restricted to 
the subgroups in which Barker et al. report the largest effect.  The one subgroup analysis 
we did not have the data to replicate was restricting the analysis of interspinous distance 
and ovarian cancer to shorter mothers.   We found no evidence (p=0.17) for this effect in 
the whole population, however, whereas in the Finnish cohort the whole-population p-
value was 0.008 (1). 
 
This non-replication cannot be attributed to insufficient power.  Our cohort is of a similar 
size to the Finnish cohort (3854 vs. 4201 females) and, because of the longer follow-up, 
contains somewhat more cancer cases (273 vs. 206 breast cancers, 52 vs. 39 ovarian 
cancers).  For example, Barker et al. report a hazard ratio for breast cancer of 1.23 per 
1cm increase in the intercristal-interspinous difference.  With 273 cancers among 3845 
women, and a standard deviation of 1.3, our cohort would have 99.4% power to detect 
this at the 5% significance level.  This non-replication likewise cannot be attributed to 
poor measurement of exposure or outcome, as both have previously shown positive 
findings in other studies.  For example, larger maternal pelvic size does protect against 
stroke in our cohort (6) in a way which replicates findings from the Finnish cohort (7).  
Similarly, breast cancer in our cohort is predicted by birth size (3) in a way consistent 
with the existing literature (8). 
 
In summary, this cohort provides no evidence that maternal pelvic size predicts 
daughters’ incidence of breast or ovarian cancers.  This therefore casts doubt on a 
relationship between these factors. 
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